FDA authorizes Omicron-specific boosters


The U.S. Food and Drug Administration on Wednesday authorized updated, Omicron-specific COVID-19 boosters from both Pfizer and Moderna, multiple outlets report.
The new shots are expected post-Labor Day, pending review from the Centers for Disease Control and Prevention later this week, notes The Washington Post. The boosters' bivalent formula targets both the BA.4 and BA.5 Omicron subvariant, as well as the original strain of the virus that circulated back in 2020.
The agency notably cleared the jabs without data from human trials, which it argued could detrimentally slow the process and perhaps render moot any data used in authorization, per The New York Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Pfizer's booster was cleared for use in individuals ages 12 and up, while the Moderna shot was authorized for those 18 and older. Prospective recipients must wait at least two months after finishing their primary series of vaccinations or after receiving their last booster dose to get the new shot.
"As we head into fall and begin to spend more time indoors, we strongly encourage anyone who is eligible to consider receiving a booster dose," FDA Commissioner Robert Califf said Wednesday.
The Biden administration is preparing to distribute the shots as part of its fall booster campaign, NBC News adds.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brigid Kennedy worked at The Week from 2021 to 2023 as a staff writer, junior editor and then story editor, with an interest in U.S. politics, the economy and the music industry.
-
Art review: Rashid Johnson: A Poem for Deep Thinkers
Feature Guggenheim New York, through Jan. 18
-
Is it worth appealing your property tax assessment?
The Explainer What to do if your property tax bill seems too high
-
Trump is trying to jump-start US manufacturing. Is it worth it?
Today's Big Question The jobs are good. The workers may not be there.
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr.: A new plan for sabotaging vaccines
Feature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments